Cargando…
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018100/ https://www.ncbi.nlm.nih.gov/pubmed/32586908 http://dx.doi.org/10.3324/haematol.2020.253450 |
| _version_ | 1783674158087929856 |
|---|---|
| author | Schjesvold, Fredrik Richardson, Paul G. Facon, Thierry Alegre, Adrián Spencer, Andrew Jurczyszyn, Artur Sunami, Kazutaka Frenzel, Laurent Min, Chang-Ki Guillonneau, Sophie Lin, Peggy L. Le-Guennec, Solenn Campana, Frank van de Velde, Helgi Bensfia, Samira Bringhen, Sara |
| author_facet | Schjesvold, Fredrik Richardson, Paul G. Facon, Thierry Alegre, Adrián Spencer, Andrew Jurczyszyn, Artur Sunami, Kazutaka Frenzel, Laurent Min, Chang-Ki Guillonneau, Sophie Lin, Peggy L. Le-Guennec, Solenn Campana, Frank van de Velde, Helgi Bensfia, Samira Bringhen, Sara |
| author_sort | Schjesvold, Fredrik |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8018100 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-80181002021-04-05 Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis Schjesvold, Fredrik Richardson, Paul G. Facon, Thierry Alegre, Adrián Spencer, Andrew Jurczyszyn, Artur Sunami, Kazutaka Frenzel, Laurent Min, Chang-Ki Guillonneau, Sophie Lin, Peggy L. Le-Guennec, Solenn Campana, Frank van de Velde, Helgi Bensfia, Samira Bringhen, Sara Haematologica Letters to the Editor Fondazione Ferrata Storti 2021-04-01 /pmc/articles/PMC8018100/ /pubmed/32586908 http://dx.doi.org/10.3324/haematol.2020.253450 Text en Copyright© 2021 Ferrata Storti Foundation http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letters to the Editor Schjesvold, Fredrik Richardson, Paul G. Facon, Thierry Alegre, Adrián Spencer, Andrew Jurczyszyn, Artur Sunami, Kazutaka Frenzel, Laurent Min, Chang-Ki Guillonneau, Sophie Lin, Peggy L. Le-Guennec, Solenn Campana, Frank van de Velde, Helgi Bensfia, Samira Bringhen, Sara Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis |
| title | Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis |
| title_full | Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis |
| title_fullStr | Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis |
| title_full_unstemmed | Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis |
| title_short | Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis |
| title_sort | isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: icaria-mm subgroup analysis |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018100/ https://www.ncbi.nlm.nih.gov/pubmed/32586908 http://dx.doi.org/10.3324/haematol.2020.253450 |
| work_keys_str_mv | AT schjesvoldfredrik isatuximabpluspomalidomideanddexamethasoneinelderlypatientswithrelapsedrefractorymultiplemyelomaicariammsubgroupanalysis AT richardsonpaulg isatuximabpluspomalidomideanddexamethasoneinelderlypatientswithrelapsedrefractorymultiplemyelomaicariammsubgroupanalysis AT faconthierry isatuximabpluspomalidomideanddexamethasoneinelderlypatientswithrelapsedrefractorymultiplemyelomaicariammsubgroupanalysis AT alegreadrian isatuximabpluspomalidomideanddexamethasoneinelderlypatientswithrelapsedrefractorymultiplemyelomaicariammsubgroupanalysis AT spencerandrew isatuximabpluspomalidomideanddexamethasoneinelderlypatientswithrelapsedrefractorymultiplemyelomaicariammsubgroupanalysis AT jurczyszynartur isatuximabpluspomalidomideanddexamethasoneinelderlypatientswithrelapsedrefractorymultiplemyelomaicariammsubgroupanalysis AT sunamikazutaka isatuximabpluspomalidomideanddexamethasoneinelderlypatientswithrelapsedrefractorymultiplemyelomaicariammsubgroupanalysis AT frenzellaurent isatuximabpluspomalidomideanddexamethasoneinelderlypatientswithrelapsedrefractorymultiplemyelomaicariammsubgroupanalysis AT minchangki isatuximabpluspomalidomideanddexamethasoneinelderlypatientswithrelapsedrefractorymultiplemyelomaicariammsubgroupanalysis AT guillonneausophie isatuximabpluspomalidomideanddexamethasoneinelderlypatientswithrelapsedrefractorymultiplemyelomaicariammsubgroupanalysis AT linpeggyl isatuximabpluspomalidomideanddexamethasoneinelderlypatientswithrelapsedrefractorymultiplemyelomaicariammsubgroupanalysis AT leguennecsolenn isatuximabpluspomalidomideanddexamethasoneinelderlypatientswithrelapsedrefractorymultiplemyelomaicariammsubgroupanalysis AT campanafrank isatuximabpluspomalidomideanddexamethasoneinelderlypatientswithrelapsedrefractorymultiplemyelomaicariammsubgroupanalysis AT vandeveldehelgi isatuximabpluspomalidomideanddexamethasoneinelderlypatientswithrelapsedrefractorymultiplemyelomaicariammsubgroupanalysis AT bensfiasamira isatuximabpluspomalidomideanddexamethasoneinelderlypatientswithrelapsedrefractorymultiplemyelomaicariammsubgroupanalysis AT bringhensara isatuximabpluspomalidomideanddexamethasoneinelderlypatientswithrelapsedrefractorymultiplemyelomaicariammsubgroupanalysis |